Cambridge Trust Co. trimmed its holdings in shares of Danaher Corporation (NYSE:DHR) by 0.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 147,983 shares of the conglomerate’s stock after selling 1,268 shares during the period. Cambridge Trust Co.’s holdings in Danaher Corporation were worth $12,694,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in DHR. Findlay Park Partners LLP lifted its holdings in Danaher Corporation by 28.1% during the 1st quarter. Findlay Park Partners LLP now owns 2,692,348 shares of the conglomerate’s stock worth $230,277,000 after buying an additional 590,000 shares during the last quarter. United Services Automobile Association lifted its holdings in Danaher Corporation by 14.8% during the 1st quarter. United Services Automobile Association now owns 413,905 shares of the conglomerate’s stock worth $35,401,000 after buying an additional 53,494 shares during the last quarter. TLP Group LLC purchased a new stake in Danaher Corporation during the 1st quarter worth about $383,000. Principal Financial Group Inc. lifted its holdings in Danaher Corporation by 38.4% during the 1st quarter. Principal Financial Group Inc. now owns 2,201,448 shares of the conglomerate’s stock worth $188,289,000 after buying an additional 610,774 shares during the last quarter. Finally, Stratos Wealth Partners LTD. lifted its holdings in Danaher Corporation by 5.6% during the 1st quarter. Stratos Wealth Partners LTD. now owns 4,063 shares of the conglomerate’s stock worth $348,000 after buying an additional 217 shares during the last quarter. 75.56% of the stock is owned by institutional investors.

DHR has been the subject of a number of recent analyst reports. Zacks Investment Research raised Danaher Corporation from a “hold” rating to a “buy” rating and set a $97.00 price target for the company in a report on Thursday, October 5th. Cowen and Company reiterated a “buy” rating and set a $90.00 target price on shares of Danaher Corporation in a research report on Wednesday, October 4th. Jefferies Group LLC reiterated a “buy” rating and set a $95.00 target price on shares of Danaher Corporation in a research report on Friday, August 4th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $83.00 target price on shares of Danaher Corporation in a research report on Tuesday, September 26th. Finally, Robert W. Baird lifted their target price on Danaher Corporation from $87.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $93.31.

Danaher Corporation (NYSE DHR) opened at $93.68 on Tuesday. The stock has a market capitalization of $65,020.00, a PE ratio of 23.99, a P/E/G ratio of 2.22 and a beta of 1.02. Danaher Corporation has a 52-week low of $76.27 and a 52-week high of $93.86. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00.

Danaher Corporation (NYSE:DHR) last issued its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. The firm had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.47 billion. Danaher Corporation had a return on equity of 11.29% and a net margin of 13.36%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.87 EPS. equities analysts expect that Danaher Corporation will post 3.99 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Shareholders of record on Friday, September 29th were issued a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date of this dividend was Thursday, September 28th. Danaher Corporation’s dividend payout ratio is presently 16.67%.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/cambridge-trust-co-sells-1268-shares-of-danaher-corporation-dhr/1717395.html.

In other Danaher Corporation news, SVP Daniel Raskas sold 37,870 shares of Danaher Corporation stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total value of $3,534,407.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Donald J. Ehrlich sold 10,578 shares of Danaher Corporation stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $90.82, for a total value of $960,693.96. Following the completion of the sale, the director now directly owns 104,621 shares in the company, valued at approximately $9,501,679.22. The disclosure for this sale can be found here. Insiders sold a total of 317,498 shares of company stock worth $28,838,801 in the last ninety days. 12.20% of the stock is owned by corporate insiders.

Danaher Corporation Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Institutional Ownership by Quarter for Danaher Corporation (NYSE:DHR)

Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.